Navigation Links
Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
Date:11/4/2010

BURLINGTON, Mass., Nov. 4, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that biosimilar erosion of branded erythropoietin stimulating agent (ESA) market share is likely to be more rapid and more complete in the United States compared to biosimilar erosion seen in Europe since biosimilar ESAs entered the European market in 2007. According to Biosimilars Advisory Service: Physician Perspectives on Erythropoietin Stimulating Agents, Insulin, and Human Growth Hormone, Decision Resources expects the timeline for the uptake of biosimilars among U.S. nephrologists will be fairly aggressive.

More than half of surveyed U.S. physicians anticipate they will begin prescribing a biosimilar ESA within six months of its launch and 88 percent expect to be using biosimilar ESAs within a year. In contrast, the majority of surveyed German nephrologists did not begin using biosimilar ESAs until the drugs had been on the market for 13-24 months. Uptake of biosimilars among surveyed French nephrologists has been even more conservative—60 percent of surveyed physicians report they still do not prescribe biosimilars ESAs.

Decision Resources forecasts that branded ESAs across the seven major pharmaceutical markets (U.S., France, Germany, Italy, Spain, United Kingdom and Japan) will lose $3 billion in combined sales to biosimilar erosion in 2019 alone, and $17.3 billion in combined sales to biosimilar erosion over Decision Resources' 2009-2019 forecast period.

"The global ESA market will be characterized by pricing pressures from a declining market and multiple biosimilar competitors," said Decision Resources Analyst MaryEllen Klusacek, Ph.D. "Biosimilars' lower costs compared with branded biologics will likely be the primary driver of both U.S. and European nephrologists' prescribing of biosimilar ESAs."

The Physician Perspectives on Erythr
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Oncologists Will Be More Aggressive In Adopting Biosimilars Compared With Other Specialties
2. Hospira Receives TGA Approval for Nivestim™, Australias First Biosimilar Filgrastim
3. PAREXEL Consulting Thought Leaders Provide Insights Into U.S. Biosimilar Development and Monoclonal Biosimilars in Two New White Papers
4. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
5. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
6. ReportsandReports: Biosimilars Series - Forecast Analysis Market Research Report
7. Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
8. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
9. The Epilepsy Drug Market Will Remain Relatively Flat Through 2019 as Generic Erosion, Especially Within the Second-Generation Antiepileptic Drug Class, is Offset by the Launch of New Therapies
10. Owing to Generic Erosion of Key Agents, the Colorectal Cancer Drug Market Will Remain Relatively Flat Through 2019
11. Through 2019, Increased Generic Erosion of Key Agents Such as Lamictal and Depakote/Depakote ER Will Cause a Precipitous $2.3 Billion Decline in the Bipolar Disorder Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 The Wolf Administration today ... Pennsylvania State Police and local ... naloxone. Heroin and opioid overdose are the ... , killing more individuals than those involved in ... died from a drug overdose. " ...
(Date:8/31/2015)... 2015  The departments of Drug and Alcohol Programs ... Concept 90 to raise awareness for International Overdose Awareness ... Pennsylvania and help more Pennsylvanians with ... through the Building Bridges to Recovery initiative. ... day to a disease that is fully treatable, if ...
(Date:8/31/2015)... -- Dipexium Pharmaceuticals, Inc. (NASDAQ: DPRX ), a late-stage ... Locilex® (pexiganan cream 0.8%), a novel, broad spectrum, topical ... investor conferences in September. , ... LLC Emerging Growth Conference in New ... President & Chief Executive Officer, will present a corporate ...
Breaking Medicine Technology:Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Pennsylvania Departments of Drug & Alcohol Programs and Health Kick-off Second Annual Building Bridges to Recovery Initiative 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 2Dipexium Pharmaceuticals Announces Participation in Four Investor Conferences in September 3
... First-in-Class Biologic Treatment Option Now Available for ... Use in Pediatric Patients with JIA(1,2) -, PRINCETON, ... ) today announced that the U.S. Food and Drug,Administration (FDA) ... patients six years and older with moderately to,severely active polyarticular ...
... Model Created Using Piecewise Smooth Subdivision Surface Provides Both ... of Fallot Patients, SEATTLE, April 8, 2008 ... and volumetric insights,that help cardiologists diagnose and treat patients ... in the American Journal,Cardiology (2008; Vol. 101, Issue 1, ...
Cached Medicine Technology:U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 2U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 3U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 4U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 5U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 6U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 7U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 8U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 9U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older 10Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 2Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology 3
(Date:9/1/2015)... ... September 01, 2015 , ... SC&H Group, a leading audit, ... being named a “Best of the Best” firm in the U.S., as well as ... “Best of the Best” in the U.S., selected exclusively on performance in specific areas ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... 2015-2016 Distinguished Nurse Scholar-in Residence at the Institute of Medicine (IOM) of the ... Biomedical Informatics at Columbia University School of Nursing. A member of the Institute ...
(Date:9/1/2015)... ... , ... Ogawa’s new massage chairs tout innovative functionality that change the way ... before. With the goal of bringing wellness to the world, Ogawa introduces their new ... As in its name, the Ogawa Refresh aims to “refresh” and rejuvenate ...
(Date:9/1/2015)... ... September 01, 2015 , ... Situations requiring fast, easy-to-understand business ... most convenient time for everyone involved. These occasions highlight the value of a ... Services has real people available to handle any translation assignment at any ...
(Date:9/1/2015)... ... ... Dr. Trace Curry successfully placed one of the first ORBERA™ Intra-gastric Balloons ... FDA has approved two intra-gastric balloons, the ORBERA ™ Managed Weight Loss System ... weight loss procedures available to Americans. , Dr. Curry, medical director at ...
Breaking Medicine News(10 mins):Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2Health News:Columbia Nursing’s Suzanne Bakken Named Distinguished Institute of Medicine Nurse Scholar-in-Residence 2Health News:Ogawa World USA Releases New Massage Chairs to the US 2Health News:Ogawa World USA Releases New Massage Chairs to the US 3Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2
... VSCP ), a leading provider of quantitative ... the company,s chief executive,officer, will be presenting a corporate ... Conference at the Waldorf Astoria in New York City. ... at 3:45pm EST. , A ...
... finds all breaks, not just hip fractures, tied to increased ... fracture that occurs in people over age 60 needs to ... the Australian researchers found the risk of dying goes up ... for at least 10 years after a hip fracture. , ...
... former Senator Tom Daschle withdrew his name for consideration ... Human Services Department (HHS). From the beginning Senator ... for President Obama for a government takeover of our ... record while in the Senate, Family Research Council has ...
... Nearly three out of four Americans (71 ... cost of addiction treatment - yet most consumers ... would pay for substance abuse treatment, according to ... Hazelden, the national nonprofit organization that helps people ...
... until third year, study finds , , TUESDAY, Feb. ... period" for hormone replacement therapy has been identified ... that using estrogen-plus-progesterone therapy increases the risk for ... than taking estrogen alone. , The finding follows ...
... One-fifth of women who should receive radiation after a ... to a new study from researchers at the University ... at 396 women who were treated with a mastectomy ... of women who fell clearly within guidelines recommending radiation ...
Cached Medicine News:Health News:VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference 2Health News:Fractures in Older Adults Up Death Risk 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 2Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 3Health News:Three-Quarters of Americans Believe Health Insurance Should Pay for Addiction Treatment, Yet Most Don't Know If Their Health Plan Covers Substance-Abuse Care, Says New Hazelden Survey 4Health News:2 Years of Hormone Use May Be 'Safe' 2Health News:19 percent of breast cancer patients don’t receive recommended radiation after mastectomy 2
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
Saline Solution to rinse and store soft contact lenses and for heat disinfection....
Sensitive Eyes Plus Saline Solution to rinse soft contact lenses The unique, gentle, pH-balanced formula contains potassium, an ingredient found in tears....
Medicine Products: